Insider Selling: Cellebrite DI (NASDAQ:CLBT) CRO Sells 12,658 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the sale, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Marcus Jewell also recently made the following trade(s):

• On Tuesday, May 12th, Marcus Jewell sold 383 shares of Cellebrite DI stock. The shares were sold at an average price of $13.01, for a total value of $4,982.83.

Cellebrite DI Stock Performance

CLBT stock opened at $13.63 on Tuesday. The firm has a fifty day moving average price of $13.51 and a 200 day moving average price of $15.48. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98. The firm has a market cap of $3.40 billion, a PE ratio of 48.68, a price-to-earnings-growth ratio of 1.99 and a beta of 1.15.

Analysts Set New Price Targets

CLBT has been the subject of a number of recent research reports. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

Institutional Trading of Cellebrite DI

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Ashford Capital Management Inc. grew its holdings in shares of Cellebrite DI by 5.5% in the first quarter. Ashford Capital Management Inc. now owns 1,762,937 shares of the company’s stock worth $24,293,000 after purchasing an additional 92,092 shares during the last quarter. Quantinno Capital Management LP purchased a new position in Cellebrite DI in the 1st quarter worth about $150,000. Lazard Asset Management LLC bought a new stake in Cellebrite DI during the 1st quarter valued at about $2,134,000. Progeny 3 Inc. purchased a new stake in Cellebrite DI in the 1st quarter valued at about $15,546,000. Finally, ABS Direct Equity Fund LLC purchased a new stake in Cellebrite DI in the 1st quarter valued at about $3,445,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.